There is a major scientific interest in the diagnosis and treatment of structural heart diseases. Cardiomyopathies, congenital heart diseases and, heart valve diseases have a marked impact on loss of physical function, quality of life, and longevity. In the next two decades, these conditions can be expected to increase sharply with the worldwide population ageing. In this scenario, tissue and serum biomarkers have the potential to be useful in the evaluation of aspects that still lack information in the area of structural heart disease. Potential biomarkers for structural heart disease can be broadly categorized into electrophysiological, morphological and molecular markers. They may reflect the underlying mechanisms of the neurohormonal cascade, soluble biomarkers of inflammation, fibrosis, polymorphisms of the ACE and convertases. These serum markers are useful for understanding the pathophysiology, providing more accurate risk stratification and helping to identify the optimal timing and monitoring of cardiac interventions.
The objective of this Research Topic is to enrich medical literature on biomarkers in structural cardiovascular disease, ranging from pathophysiology to follow-up after the intervention. To achieve this all manuscript types will be accepted. This Research Topic focuses on the biomarkers assessment in structural cardiovascular disease, with a particular interest in screening, diagnosis and prognosis information.
The topics shall include, but not limited to, the most recent progress in the below areas:
1) Use of biomarkers in disease severity definition.
2) Use of biomarkers in cardiac and pulmonary repercussion evaluation.
3) Role of biomarkers in risk prediction.
4) Development of risk score models.
5) Use of biomarkers in disease progression monitoring.
6) Role of biomarkers in therapeutic monitoring.
7) Use of biomarkers in postoperative outcomes prediction.
There is a major scientific interest in the diagnosis and treatment of structural heart diseases. Cardiomyopathies, congenital heart diseases and, heart valve diseases have a marked impact on loss of physical function, quality of life, and longevity. In the next two decades, these conditions can be expected to increase sharply with the worldwide population ageing. In this scenario, tissue and serum biomarkers have the potential to be useful in the evaluation of aspects that still lack information in the area of structural heart disease. Potential biomarkers for structural heart disease can be broadly categorized into electrophysiological, morphological and molecular markers. They may reflect the underlying mechanisms of the neurohormonal cascade, soluble biomarkers of inflammation, fibrosis, polymorphisms of the ACE and convertases. These serum markers are useful for understanding the pathophysiology, providing more accurate risk stratification and helping to identify the optimal timing and monitoring of cardiac interventions.
The objective of this Research Topic is to enrich medical literature on biomarkers in structural cardiovascular disease, ranging from pathophysiology to follow-up after the intervention. To achieve this all manuscript types will be accepted. This Research Topic focuses on the biomarkers assessment in structural cardiovascular disease, with a particular interest in screening, diagnosis and prognosis information.
The topics shall include, but not limited to, the most recent progress in the below areas:
1) Use of biomarkers in disease severity definition.
2) Use of biomarkers in cardiac and pulmonary repercussion evaluation.
3) Role of biomarkers in risk prediction.
4) Development of risk score models.
5) Use of biomarkers in disease progression monitoring.
6) Role of biomarkers in therapeutic monitoring.
7) Use of biomarkers in postoperative outcomes prediction.
